San Diego ophthalmic biotech upstart raises $28M on alternative to corneal transplant
Texas VC Bios Partners has found a new early-stage play to love out of San Diego, leading a $28 million Series A to help Trefoil Therapeutics make the leap to the clinic.
Stella Robertson, who headed R&D at Novartis’ eye care unit Alcon before co-founding Bios Partners, is particularly excited about this one. With a tech platform that engineers fibroblast growth factor-1 protein (FGF-1), Trefoil is out to tackle serious corneal endothelial diseases and epithelial disorders by prompting the endothelial cells to flourish and migrate. Ultimately — if the preclinical data hold up — the goal is to enhance healing and reverse vision loss.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.